MultiplexDX showcases breakthrough at ESMO in Berlin
MultiplexDX participated in the prestigious ESMO Breast Cancer 2024 conference, held in Berlin. This renowned event is a key platform for experts in breast cancer research and treatment, attracting leading oncologists, specialists, and researchers from around the world.
At the conference, we presented our advanced diagnostic test for breast cancer patients, earning recognition for its innovative approach. The event provided us with a unique opportunity to engage with Europe’s leading experts in breast cancer research and treatment. Our team shared insights into their contributions to advancing diagnostic precision and personalized treatment strategies.
Adding to the company’s accomplishments, ESMO Open, a platform for high-quality, peer-reviewed research in oncology and related fields, published our abstract titled "36P Multiplexed RNA-FISH-guided laser capture microdissection RNA sequencing improves breast cancer molecular subtyping and prognostic classification."
For more information, read full abstract.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
